NASDAQ Biotech/Pharma Market Leaders; (NASDAQ:BPAX), (NASDAQ:AMGN), (NASDAQ:LIFE) Stocks to Follow for Wednesday

Visit this company: www.biosantepharma.com Point Roberts, WA - November 3, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Snapshot featuring some of the NASDAQ�s Actively traded market leaders for today. Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner Biotech /Pharma Sector Trading Snapshot: (as of time of release November 3rd) * BioSante Pharmaceuticals, Inc. BPAX trading at $1.52, up 0.02 (1.33%) * Amgen Inc. AMGN, trading at $57.40, up .04 (0.07%) * Life Technologies Corporation LIFE trading at $ 50.71, up 0.22 (0.44%) Market Summary: * Dow 11,211.88 +23.16 +0.21% * NASDAQ 2,534.96 +1.44 +0.06% * S&P 500 1,195.23 +1.66 +0.14% * 10 Yr Bond (%) 2.5490% -0.0450 * Oil 84.42 +0.52 +0.62% * Gold 1,353.00 -3.40 -0.25% Biotech/Pharma Stocks Recent News; BioSante Pharmaceuticals, Inc. BPAX Reports Positive LibiGel� Data Monitoring Committee Recommendation No safety issues observed, study to continue as per protocol without modifications LINCOLNSHIRE, Ill. - (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. BPAX today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product. Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp More news - Visit the BPAX showcase profile at Investorideas.com http://www.investorideas.com/CO/BPAX/ Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com Life Technologies Corporation LIFE News: Life Technologies Launches New SOLiD Sequencer to Drive Advances in Cancer Biology and Genetic Disease Research "Life Technologies Corporation a provider of innovative life science solutions, today announced the launch of the 5500xl SOLiD™ Sequencer, a new instrument designed to deliver the industry's fastest and most accurate genomic data for cancer biology and genetic disease research. Developed and manufactured with long-standing partner Hitachi High-Technologies, the 5500xl delivers on the promise of the SOLiD 4hq, which was first announced in January. Initial shipments of the 5500xl are planned for December 2010." Full Article: http://finance.yahoo.com/news/Life-Technologies-Launches-bw-2424991704.html?x=0&.v=1 About Life Technologies Corporation LIFE Life Technologies Corporation LIFE is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com. Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp More info on BPAX: BioSante Pharmaceuticals, Inc. BPAX Investor Fact Sheet update and News: Full Media Kit at: http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf Financial Highlights * At September 30, 2010, BioSante had approximately $36M in cash * Monthly burn rate of approximately $3.5M Investment Highlights * Financial resources to implement plan * Late stage pharmaceutical product portfolio with significant growth potential * LibiGel in three ongoing Phase III safety and efficacy clinical studies * Elestrin is FDA approved and marketed in the U.S. * Proprietary cancer vaccines in Phase II clinical trials * Focused growth strategy * Management's proven ability to gain FDA approval, implement plans and increase stockholder value About InvestorIdeas.com: InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, the Middle East and Australia. Sign up for free stock alerts on biotech stocks and other leading sectors! http://www.investorideas.com/Resources/Newsletter.asp About our Biotech investor portal: www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories. Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX (three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising. More info: Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp C Van Zant: 800-665-0411 - cvanzant@investorideas.com Source - Investorideas.com More Info: Published at www.Investorideas.com - Global research by sectors If you have any questions regarding information in this press release please contact the company listed in the press release.